Grant: CIHR Fellowship
Direct Payment
$125,000.00
Exploring the actions of autoantibodies in fibromyalgia
EF 2019-20
Résumé
Fibromyalgia is characterized by widespread pain and tenderness. Between 1.5 and 10% of the population suffer from fibromyalgia, but despite this high prevalence no diagnostic tests exist and current therapies have limited effect. We know very little about the causes of fibromyalgia, which is partly why fibromyalgia is diagnosed with a list of criteria, rather than tests, and why current treatment strategies are so limited. We recently discovered that injecting antibodies from fibromyalgia patients into mice causes pain-like behaviour and increased activity of pain sensing neurons. These results suggest that some fibromyalgia patients' immune systems produce autoantibodies that attack their own bodies. Therefore, autoimmunity could underlie fibromyalgia in a subset of patients. Our findings have the potential to change how fibromyalgia is viewed and how it is treated. In this project we will build on our findings to better understand how fibromyalgia autoantibodies cause pain.
First, we will search for the protein(s) fibromyalgia antibodies recognize. Identifying which proteins antibodies bind to will provide information about how they could drive pain. Additionally, these results can open the door to the creation of diagnostic tests based on the presence of specific antibodies, similar to the tests used in rheumatoid arthritis, rather than on a certain number of symptoms. Second, we will investigate how fibromyalgia antibodies increase the activity of pain sensing neurons. We have already found that fibromyalgia antibodies bind cells called satellite glial cells, which surround the cell bodies of pain sensing neurons. We will examine how fibromyalgia antibodies alter the activity of satellite cells, and how they then alter pain sensing neuron activity. Our expected results will provide the basis to develop diagnostic tests based on autoantibody presence and provide the rationale for using antibody targeting therapies to manage fibromyalgia.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Sweden
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
412619
Name
Krock Emerson
Country
Sweden
Orgtype
Research Institution
Instname2
Musculoskeletal Health and Arthritis
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Exploring the actions of autoantibodies in fibromyalgia
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$125,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Autoantibody Identification; Autoimmune; Fibromyalgia; Glia; Neuroimmune; Pain
Abstract
Fibromyalgia is characterized by widespread pain and tenderness. Between 1.5 and 10% of the population suffer from fibromyalgia, but despite this high prevalence no diagnostic tests exist and current therapies have limited effect. We know very little about the causes of fibromyalgia, which is partly why fibromyalgia is diagnosed with a list of criteria, rather than tests, and why current treatment strategies are so limited. We recently discovered that injecting antibodies from fibromyalgia patients into mice causes pain-like behaviour and increased activity of pain sensing neurons. These results suggest that some fibromyalgia patients' immune systems produce autoantibodies that attack their own bodies. Therefore, autoimmunity could underlie fibromyalgia in a subset of patients. Our findings have the potential to change how fibromyalgia is viewed and how it is treated. In this project we will build on our findings to better understand how fibromyalgia autoantibodies cause pain.
First, we will search for the protein(s) fibromyalgia antibodies recognize. Identifying which proteins antibodies bind to will provide information about how they could drive pain. Additionally, these results can open the door to the creation of diagnostic tests based on the presence of specific antibodies, similar to the tests used in rheumatoid arthritis, rather than on a certain number of symptoms. Second, we will investigate how fibromyalgia antibodies increase the activity of pain sensing neurons. We have already found that fibromyalgia antibodies bind cells called satellite glial cells, which surround the cell bodies of pain sensing neurons. We will examine how fibromyalgia antibodies alter the activity of satellite cells, and how they then alter pain sensing neuron activity. Our expected results will provide the basis to develop diagnostic tests based on autoantibody presence and provide the rationale for using antibody targeting therapies to manage fibromyalgia.
Competitiondate
201910
Approvedterm2
2 yrs 6 mths
Pinamesdelim
Krock, Emerson
Approvedterm
2 ans 6 mois
Cihrcontribution2
~ $125,000~ $0~